Agilent, 785975-906, AdvanceBio RP-mAb SB-C8, 4.6 x 100 mm, 3.5 µm

AdvanceBio RP-mAb SB-C8, 4.6 x 100 mm, 3.5 µm. A reversed-phase C8 HPLC column with superficially porous particles and a wide (450 Å) pore size designed for intact or subunit analysis of mAbs. StableBond technology ensures stability at low pH.

Specifications:
Brand: AdvanceBio RP mAb C8
Hardware: SS
Inner Diameter (ID): 4.6 mm
LC Platform: Stainless Steel
Length: 100 mm
Maximum Temperature: 90 °C
Part Number Application Domain: Biopharma
Part Number Application: Intact & Subunit AnalysisMonoclonal Antibodies (mABs)Proteins
Particle Size: 3.5 µm
Particle Type: Superficially Porous
Phase: SB-C8
Pore Size: 450 Å
Pressure Rating: 600 bar
Separation Mode: Reversed Phase
Shipping Solvent: Acetonitrile/Water
Technique: LCLC & LC/MS
UNSPSC Code: 41115711
pH Range: 1-8

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
Designed for high-performance reversed-phase chromatography, this 4.6 x 100 mm, 3.5 µm column is engineered specifically for the analysis of monoclonal antibodies and related biologics. The SB-C8 bonded phase provides optimal selectivity and retention for intact and fragmented antibodies, enabling robust, reproducible separations with high resolution. With broad compatibility across Agilent HPLC and UHPLC systems, this column is suitable for a variety of research environments, including biopharmaceutical development, quality control, and process monitoring.

Researchers can rely on this product for detailed characterization studies, including purity assessment, aggregate detection, and isoform analysis. The column demonstrates excellent stability at low and high pH, delivering consistent results with various mobile phases. It is also fully compatible with related AdvanceBio columns, facilitating method scalability and transfer. This makes it an indispensable tool for laboratories that require precise and reproducible analysis of large biomolecules. Suitable for both discovery and regulated workflows, this solution helps ensure reliable results in the development of therapeutic proteins and antibody-based drugs.